Healthcare
Eurofins Scientific SE(ERFSF)
Live Price
Offline$71.73
-6.52% today
1Y Change
+6.47%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $10.61B
- Revenue Growth
- +4.9%
- EPS Growth
- +23.9%
- Dividend Yield
- 1.2%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eurofins Scientific SE (ERFSF) is a Healthcare stock with a market cap of $10.61B and listed on OTC. The stock last traded around $71.73 and up 6.5% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +4.9%, EPS growth of +23.9%, a dividend yield of 1.2%. What stands out right now is revenue +4.9%, EPS +23.9%, free cash flow -32.3% with operating margin 15.6% and ROIC 8.9%. The dividend is present but secondary, with a yield around 1.2%. Valuation is more restrained than many high-expectation growth names at P/E 23.0 and price/sales 1.5. Stock Foundry combines ERFSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.9% vs +7.6% peer median
Operating Margin
Below sector median
+15.6% vs +19.4% peer median
P/E
Below sector median
23.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Jan 29, 2026 with an EPS surprise of +1.4% and a revenue surprise of -0.2%.
The operating story is still moving forward
Revenue is running at +4.9% and EPS at +23.9%, with operating margin around 15.6%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 29, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jan 29, 2026 | +1.4% | +1.6% | +1.5% | +0.9% |
2025 Jun 30, 2025 | -23.4% | +1.8% | -1.1% | +9.5% |
2024 Dec 31, 2024 | -35.8% | +5.8% | +2.0% | +10.5% |
Benchmark Edge
ERFSF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ERFSF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ERFSF Max Drawdown
-22.71%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ERFSF and SPY.
Company Overview
Eurofins Scientific SE
Other OTC
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
- Leadership
- Gilles G. Martin
- IPO Date
- Apr 26, 2010
- Employees
- 62.7k
- Street Address
- 23 Val Fleuri
- Mailing
- Luxembourg City, 1526
- Region
- Luxembourg City, LU
- Reporting Currency
- USD
- Investor Line
- 352 26 18 53 20
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.0
- EV/EBITDA
- 13.8
- Price/Sales
- 1.5
- Price/Book
- 3.1
Growth
- Revenue
- +4.9%
- EPS
- +23.9%
- Free Cash Flow
- -32.3%
Profitability
- Gross Margin
- 16.4%
- Operating Margin
- 15.6%
- Net Margin
- 6.5%
- ROE
- 11.6%
- ROIC
- 8.9%
Balance Sheet
- Debt/Equity
- 1.53
- Current Ratio
- 1.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.